Antimalarial drugs have usually been first deployed in areas of malaria endemicity at doses
which were too low, particularly for high-risk groups such as young children and pregnant …

Malaria is an infectious disease which disproportionately effects children and pregnant
women. These vulnerable populations are often excluded from clinical trials resulting in one …

Background Artemisinin-based combination therapies (ACTs) are the mainstay of the current
treatment of uncomplicated Plasmodium falciparum malaria, but ACT resistance is …

Mass administration of antimalarial drugs and ivermectin are being considered as potential
accelerators of malaria elimination. The safety, tolerability, pharmacokinetics, and mosquito …

Young children are the population most severely affected by Plasmodium falciparum
malaria. Seasonal malaria chemoprevention (SMC) with amodiaquine and sulfadoxine …

Aims The aims of the present study were to evaluate the pharmacokinetic properties of
dihydroartemisinin (DHA) and piperaquine, potential drug–drug interactions with …

Severe acute malnutrition (SAM) has been reported to be associated with increased malaria
morbidity in Sub‐Saharan African children and may affect the pharmacology of antimalarial …

Artemether-lumefantrine is the most widely used antimalarial artemisinin-based combination
treatment. Recent studies have suggested that day 7 plasma concentrations of the potent …

Intermittent preventive treatment (IPT) with dihydroartemisinin-piperaquine (DP) is highly
protective against malaria in children, but is not standard in malaria-endemic countries …

Amodiaquine plus artesunate is the recommended antimalarial treatment in many countries
where malaria is endemic. However, pediatric doses are largely based on a linear …